FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide

Table 3 Correlation analysis between chemotherapy and overall survival among glioma patients with high and low FXYD2 mRNA expression in CGGA

Parameter	Univariate Cox Regression			Multivariate Cox Regression
Parameter	P value	HR	95% CI (low-up)	P value	HR	95% CI (low-up)
High
Sex	0.002	1.792	1.231–2.607	0.123	1.396	0.914–2.132
Age	0.000	1.031	1.015–1.047	0.137	1.012	0.996–1.028
Recurrent	0.000	2.041	1.432–2.910	0.000	2.951	1.977–4.406
Histopathological types (HE)	0.000	2.037	1.754–2.365	0.415	0.861	0.601–1.233
2021 WHO grade	0.000	3.589	2.727–4.723	0.000	4.037	2.208–7.384
IDH mutation status	0.000	0.261	0.181–0.375	0.000	0.409	0.256–0.655
1p/19q codeletion status	0.000	0.309	0.199–0.480	0.004	0.426	0.237–0.765
MGMT methylation_status	0.021	0.729	0.558–0.952	0.015	0.710	0.539–0.935
Complete excision	0.669	1.092	0.730–1.634	0.678	0.913	0.594–1.403
Radiotherapy	0.256	1.300	0.827–2.043	0.468	0.816	0.472–1.413
Chemotherapy	0.909	1.024	0.682–1.537	0.001	0.427	0.259–0.704
Low
Sex	0.101	0.786	0.589–1.048
Age	0.000	1.023	1.011–1.035	0.024	1.014	1.002–1.026
Recurrent	0.000	1.880	1.399–2.525	0.000	1.859	1.360–2.540
Histopathological types (HE)	0.000	1.583	1.387–1.807	0.395	0.884	0.665–1.175
2021 WHO grade	0.000	2.222	1.818–2.716	0.000	2.416	1.564–3.730
IDH mutation status	0.000	0.472	0.347–0.642	0.730	0.933	0.628–1.385
1p/19q codeletion status	0.001	0.363	0.197–0.668	0.016	0.436	0.222–0.854
MGMT methylation_status	0.036	0.813	0.669–0.986	0.238	0.880	0.711–1.088
Complete excision	0.805	0.958	0.679–1.351	0.322	0.836	0.587–1.191
Radiotherapy	0.861	0.969	0.679–1.382	0.185	0.758	0.504–1.142
Chemotherapy	0.132	1.310	0.922–1.862	0.279	0.788	0.512–1.213

ISSN: 1471-2377